Orchid Pharma's Cephalexin approved by USFDA, EDQM
By Our Corporate Bureau | 24 Feb 2003
Chennai: Orchid Chemicals & Pharmaceuticals, the city-based bulk drug major, has announced that its product Cephalexin has been formally approved by the US Food and Drugs Administration (USFDA).
According to the company, the product has also been granted the Certificate of Suitability (CoS) by the European Directorate for the Quality of Medicines (EDQM).
“We are extremely happy about these developments. Both these milestones will definitely enable a stronger entry into the US and European markets. We hope to take more of our products through the USFDA approval this year, based on established manufacturing facilities as well as new facilities under commissioning,“ says Orchid managing director K Raghavendra Rao.
Latest articles
Featured articles
Post-splashdown: What Artemis II taught us about the ‘deep space wall’
By Axel Miller | 15 Apr 2026
Artemis II splashdown marks a breakthrough in deep space exploration. Discover AVATAR radiation data, Orion’s distance record, and insights shaping NASA’s 2028 Moon mission.
Can aviation go green? The multi-billion dollar race for sustainable fuel
By Cygnus | 10 Apr 2026
Airlines are racing to adopt sustainable aviation fuel, but limited supply and high costs challenge the future of green aviation.
The battery race: who will control the future of electric vehicles?
By Axel Miller | 08 Apr 2026
The global battery race is reshaping the electric vehicle industry, with China, the US, and Europe competing for control over supply chains and technology.
AI vs governments: Who controls the future of intelligence?
By Cygnus | 07 Apr 2026
Governments and AI companies like OpenAI and Anthropic are shaping the future of intelligence amid rising policy conflicts and global competition.
Strait of Hormuz: how one chokepoint controls the global economy
By Axel Miller | 06 Apr 2026
The Strait of Hormuz is a critical global chokepoint. Learn how disruptions impact oil prices, shipping, and the global economy.
The $2 trillion AI infrastructure race: Who will control global compute?
By Cygnus | 06 Apr 2026
AI spending is set to exceed $2 trillion in 2026, driving a global race in data centers, chips, and energy infrastructure.
.webp)
Artemis II and the economic outlook for lunar infrastructure
By Axel Miller | 01 Apr 2026
Artemis II will test deep-space systems and support future lunar missions, shaping the next phase of the global space economy.
Synthetic diplomacy: The $50 billion mirage and the new era of market-moving deepfakes
By Cygnus | 30 Mar 2026
Synthetic diplomacy shows how deepfakes could trigger market volatility, highlighting the growing need for verification in global financial systems.
AI war shifts gears: chips, drones reshape global power
By Cygnus | 27 Mar 2026
AI competition is shifting as chips, drones and supply chains reshape global power, impacting tech, defense and business strategies.
Latest articles
